國家衛生研究院 NHRI:Item 3990099045/10632

NHRI > National Institute of Infectious Diseases and Vaccinology > Shu-Ching Hsu > Periodical Articles > Item 3990099045/10632

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/10632

Title:	Elimination of undifferentiated human embryonic stem cells by cardiac glycosides
Authors:	Lin, YT;Wang, CK;Yang, SC;Hsu, SC;Lin, H;Chang, FP;Kuo, TC;Shen, CN;Chiang, PM;Hsiao, M;Lu, FL;Lu, J
Contributors:	Division of Vaccine Research and Development
Abstract:	An important safety concern in the use of human pluripotent stem cells (hPSCs) is tumorigenic risk, because these cells can form teratomas after an in vivo injection at ectopic sites. Several thousands of undifferentiated hPSCs are sufficient to induce teratomas in a mouse model. Thus, it is critical to remove all residue-undifferentiated hPSCs that have teratoma potential before the clinical application of hPSC-derived cells. In this study, our data demonstrated the cytotoxic effects of cardiac glycosides, such as digoxin, lanatoside C, bufalin, and proscillaridin A, in human embryonic stem cells (hESCs). This phenomenon was not observed in human bone marrow mesenchymal stem cells (hBMMSCs). Most importantly, digoxin and lanatoside C did not affect the stem cells' differentiation ability. Consistently, the viability of the hESC-derived MSCs, neurons, and endothelium cells was not affected by the digoxin and lanatoside C treatment. Furthermore, the in vivo experiments demonstrated that digoxin and lanatoside C prevented teratoma formation. To the best of our knowledge, this study is the first to describe the cytotoxicity and tumor prevention effects of cardiac glycosides in hESCs. Digoxin and lanatoside C are also the first FDA-approved drugs that demonstrated cytotoxicity in undifferentiated hESCs.
Date:	2017-07-13
Relation:	Scientific Reports. 2017 Jul 13;7:Article number 5289.
Link to:	http://dx.doi.org/10.1038/s41598-017-05616-2
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2045-2322&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000425910400001
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85024103546
Appears in Collections:	[Shu-Ching Hsu] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB28706279.pdf		4473Kb	Adobe PDF	391	View/Open

Loading...